{"organizations": [], "uuid": "2ecfac1cf35d49c669e6fc7adedfeacc49074c58", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/26/globe-newswire-2018-first-half-year-financial-results-webcast-for-mesoblast.html", "country": "US", "domain_rank": 767, "title": "2018 First Half Year Financial Results Webcast for Mesoblast", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-02-27T00:00:00.000+02:00", "replies_count": 0, "uuid": "2ecfac1cf35d49c669e6fc7adedfeacc49074c58"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/26/globe-newswire-2018-first-half-year-financial-results-webcast-for-mesoblast.html", "ord_in_thread": 0, "title": "2018 First Half Year Financial Results Webcast for Mesoblast", "locations": [], "entities": {"persons": [{"name": "mesoblast", "sentiment": "none"}], "locations": [{"name": "melbourne", "sentiment": "none"}, {"name": "australia", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "msb", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK and MELBOURNE, Australia, Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST on Tuesday, February 27, 2018; 8:30 am Wednesday, February 28, 2018 AEDT.\nThe live webcast can be accessed via\nhttp://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22\nTo access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 882151.\nThe archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com\nAbout Mesoblast\nMesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.\nFor further information, please contact:\nJulie Meldrum\nCorporate Communications\nMesoblast Limited\nT: +61 3 9639 6036\nE: julie.meldrum@mesoblast.com\nSchond Greenway\nInvestor Relations\nMesoblast Limited\nT: +1 212 880 2060\nE: schond.greenway@mesoblast.com\nSource:Mesoblast Limited", "external_links": ["https://www.globenewswire.com/Tracker?data=XLAgdgAYtFzYQkyhRWPvKxKA1DBYZkDNQZYoZZS1JbJn3PraugItPLpqJsN3dTEoOt2Bw7YOcP5V44ltsbGK1xorRVTr2gQe2-u8SmWBVW7TcFfebGo4xLzV3NOMlAPf", "https://www.globenewswire.com/Tracker?data=4SXZ3dL3iIC51aVPlw2gDsCkYR6LVVgkqCayXnvIHjfDSHQNoP1HPWVrvSr_XN2_Fc3QQzWvOXWmF_93OXabIA==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/1c99bb36-c17b-469c-b838-bc7244df06f2", "https://www.globenewswire.com/Tracker?data=SDnxrQoUc0OK73LUbsmu7E3lYsOPvujwXDBOesS14ixGp_N--mwliw31y-6ikbxdIMiOUFLkMds-vrlpZT2Ue3ACP5QkpZuGkGen6vuOEQ2eSjsf4Pxf7_FzqDWIx0qmCjt9x4HXOhrR9wYsuP7kEAJqBp-zVkL8SR6dhdnaN8yWwneglmffjzrq0DqTpWHv_L6MHORK6-Lanx-806onaw==", "https://www.globenewswire.com/Tracker?data=5zonRdpculLu4FCcmAUR6hhSp2WHru1wFx5P91vLZLtox1CX00uIrqPm1YDj6UcnBaopHxIVxIfXHOuyMr4ydG121p97RhPq5QKEVg4P_agGMJhEX0goqpnJ9SnNCkbY", "http://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22"], "published": "2018-02-27T00:00:00.000+02:00", "crawled": "2018-02-27T01:13:22.012+02:00", "highlightTitle": ""}